Oxford coronavirus vaccine candidate is 70% effective says AstraZeneca

November 22, 2020

Patent waiver seen stalling vaccine production in Nigeria

COVAX has secured enough vaccines to achieve 45 percent of coverage across countries by the middle of this year

Drugmaker AstraZeneca announced on Monday that its experimental coronavirus vaccine has shown an average efficacy of 70% in its large scale trials — the latest of several vaccine trials worldwide to post their results this month.

The vaccine, developed with the University of Oxford, showed 90% efficacy in one dosing regimen, and 62% efficacy in a second regimen. That averages to a 70% efficacy, AstraZeneca said.

The company said in a news release that its vaccine was “highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine.”

The interim analysis included a total of 131 Covid-19 cases, according to the release.

This comes after Moderna announced earlier this month that its vaccine was 94.5% effective against coronavirus, and Pfizer announced its vaccine was 95% effective.